Novexel initiates second Phase II intra-abdominal infections trial
Novexel, a specialty pharmaceutical company, has announced that its most advanced injectable antibacterial, which combines the company’s broad spectrum beta lactamase inhibitor, NXL104, with the well established cephalosporin
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.